Notice

Because of a lapse in government funding, the information on this website may not be up to date, transactions submitted via the website may not be processed, and the agency may not be able to respond to inquiries until appropriations are enacted.

Updates regarding government operating status and resumption of normal operations can be found at USA.gov.

Technology Development Recent Happenings

Inventors Recognition Program

United States Patent 9,663,812 was issued on May 30, 2017 for an Adapter for suspending a cryovial over a centrifuge tube.  NIAID inventors: Mario Roederer, Ph.D.,  Margaret Beddall,  Pratip Chattopadhyay, Ph.D.

United States Patent 9,695,230 was issued on July 4, 2017 for Broadly neutralizing HIV-1 VRC07 antibodies that bind to the CD4-binding site of the envelope protein.  NIAID Inventor: Peter Kwong, Ph.D 

United States Patent 9,701,718 was issued on July 11, 2017, for Adenovirus serotype 26 and serotype 35 filovirus vaccines.  NIAID inventors Nancy Sullivan, Ph.D., Cheng Cheng 

United States Patent 9,730,993 was issued on August 15, 2017 for Engineered anthrax lethal toxin for targeted delivery.  NIAID inventor: Stephen H. Leppla, Ph.D.

United States Patent 9,771,428 was issued on September 26, 2017 for CD47 targeted therapies for the treatment of infectious disease .  NIAID inventors: Kim Hasenkrug, Ph.D.

United States Patent 9,775,895 was issued on October 3, 2017 for HIV therapeutics and methods of making and using same.  NIAID inventor: Paolo Lusso, M.D., Ph.D.

United States Patent  9,783,596  was issued on October 10, 2017, for Humanized monoclonal antibodies that specifically bind and/or neutralize Japanese encephalitis virus (JEV) and their use.  NIAID inventor: Robert Purcell, M.D., (retired).

United States Patent 9,795,662 was issued on October 24, 2017 for Vaccine comprising AMA1 and RON2.   NIAID inventors: Prakash Srinivasan, Ph.D., Louis Miller, M.D.

Recent Patents

United States patent 9,683,269 was issued on June 20, 2017, for Infectious hepatitis C viruses of genotype 3A and 4A and uses thereof. NIAID inventors: Jens Bukh, M.D.

United States patent 9,783,787 was issued on October 10, 2017, for Dengue tetravalent vaccine containing a common 30 nucleotide deletion in the 3'-UTR of dengue types 1, 2, 3, and 4, or antigenic chimeric dengue viruses 1, 2, 3, and 4. NIAID inventors: Stephen S. Whitehead, Ph.D.Joseph E. Blaney, Ph.D., M.B.A.

United States patent 9,783,595 was issued on October 10, 2017, for Neutralizing GP41 antibodies and their use. NIAID inventors: Mark Connors, Ph.D., John R. Mascola, M.D., Baoshan Zhang Rebecca S. Rudicell

United States patent 9,815,887 was issued on November 14, 2017 for Monoclonal antibodies that neutralize a norovirus. NIAID inventors: Zhaochun Chen, Ph.D., Lisbeth Kim Green, Ph.D.Karin Bok, MS, Ph.D.

United States patent 9,845,350 was issued on December 19, 2017, for Monoclonal antibodies that react with the capsule of bacillus anthracis. NIAID inventors: Zhaochun Chen, Ph.D., Joanna Kubler-Kielb, Ph.D.

United States patent 9,850,468 was issued on December 26, 2017, for Infectious hepatitis E virus genotype 3 recombinants. NIAID inventors: Hanh T. Nguyen

Recent Collaborative Agreements

NIAID and Amgen Inc. signed a material study of the CD300 family of receptors in collaboration with Bristol-Myers Squibb Company, for understanding their involvement in cancer and other inflammatory diseases to study the relative significance of IL17-RA and the adaptor protein CIKS in signaling by members of the IL-17 family of cytokines. NIAID principle investigator: Ulrich K. Siebenlist.

NIAID and MERCK SHARP & DOHME CORP. signed a human research collaboration agreement (RCA) to develop non-human primate challenge studies by Merck through its contractor and adds materials from NIAID. NIAID principle investigator: Richard A. Koup

NIAID and MERCK SHARP & DOHME CORP. signed a research collaboration agreement (RCA) to generate and test novel multi-specific antibodies for treatment of HIV-1 infection. NIAID principle investigator: Richard A. Koup

NIAID and the Broad Institute of MIT signed a research collaboration agreement (RCA) to utilize antisense oligonucleotides (ASOs) to silence the gene for human prion protein. NIAID principle investigator: Byron W. Caughey

NIAID and MaxCyte Inc. signed a research collaboration agreement (RCA) to develop a cell engineering process for ex vivo gene correction in autologous CD34+ hematopoietic stem cells for treatment of hereditary diseases. NIAID principle investigator: Harry L. Malech

NIAID and CureVac AG signed a cooperative research and development agreement (CRADA) to collaborate on mRNA vaccines and therapeutics for Filoviruses. NIAID principle investigator: Nancy J. Sullivan

NIAID and University of Brescia, Italy signed a human research collaboration agreement (RCA) to send human samples (DNA, Blood) to NIAID for genotyping and follow-up studies related to mast cells and tryptase. NIAID principle investigator: Joshua D. Milner

NIAID and Health Partners Institute signed a human research collaboration agreement (RCA) to transfer human samples from patients with systemic capillary leak syndrome (SCLS) to Dr. Dudek. NIAID principle investigator: Kirk M. Druey

NIAID and the San Diego VA Medical Center signed a human research collaboration agreement (RCA) to send de-identified patient samples to.characterize the phenotype of patients with physically induced urticaria.NIAID principle investigator: Dean D. Metcalfe

NIAID and PATH Malaria Vaccine Initiative (MVI) signed a human research collaboration agreement (RCA) to test new high sensitivity RDT kits, and identify individuals harboring low density Plasmodium falciparum infections and their contribution to transmission. NIAID principle investigator: Patrick E. Duffy

NIAID, Vaccine Research Center, and King's College London (KCL) signed a research collaboration agreement (RCA) to collaborate and study the physical and genetic properties of immune cells in blood collected from a large cohort of twins.NIAID principle investigator: Mario Roederer

NIAID and Bristol-Myers Squibb Company are collaborating to study the CD300 family of receptors to understand their involvement in cancer and other inflammatory diseases. NIAID principle investigator: John E. Coligan

NIAID and The National Institute for Communicable Diseases (“NICD”), the Centre for the AIDS Programme of Research in South Africa (“CAPRISA”) and the Vaccine Research Center (VRC) signed a research collaboration agreement (RCA) to characterize longitudinal samples from HIV-1 positive subjects from the CAPRISA clinical studies. NIAID principle investigator: John R. Mascola

NIAID and the University of Washington signed a research collaboration agreement (RCA) to focus on understanding the structure-function aspects of viral pathogen associated molecular pattern (PAMP) RNA binding to RIG-I. NIAID principle investigator: Joseph Marcotrigiano

NIAID and Griffith University (GU), Gold Coast Campus signed a research collaboration agreement (RCA) to transfer NIAID’s TBV antigen Pfs25 to GU researchers to incorporate a multi-component malaria vaccine.to be tested in mice. NIAID principle investigator: Patrick E. Duffy

NIAID and Roche Innovation Center signed a research collaboration agreement (RCA) to assess histo-cytometry and tissue clearing methods. NIAID principle investigator: Ronald N Germain

NIAID and Oxford University signed a research collaboration agreement (RCA) to request chAd-Ox1 plasmids for use in CCHF research. NIAID principle investigator: Heinz U. Feldmann

NIAID and University of Melbourne, AU signed a research collaboration agreement (RCA) to study and develop improved vaccines against influenza and other viral diseases. NIAID principle investigator: Barney S Graham

NIAID and Leica Microsystems, Inc. signed a research collaboration agreement (RCA) to assess histo-cytometry and tissue clearing methods. NIAID principle investigator: Ronald N. Germain

NIAID, Juno Therapeutics, and Fred Hutchinson Cancer Research Center (FHCRC), signed a research collaboration agreement (RCA) to construct chimeric antibody receptor (“CAR”) T cells using antibody binding receptors to SIV, and using VRC07-523 antibody binding receptor(s) to HIV.NIAID principle investigator: John R. Mascola

Content last reviewed on January 18, 2018